Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

N/ATemporarily Not AvailableNCT00596115

Bennett, James P., Jr., M.D., Ph.D.

Overview

R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Study Type

EXPANDED_ACCESS

Conditions

Amyotrophic Lateral Sclerosis

Interventions

R(+) pramipexole dihydrochloride monohydrateDRUG

20 mg tid per day orally

Eligibility

Sex: ALLMin age: 30 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Definite diagnosis of ALS Exclusion Criteria: * No prior participation in R(+)PPX clinical studies

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.